FDA hits Nat­co with warn­ing let­ter over In­dia fa­cil­i­ty, sus­pends prod­uct ship­ments to US

Man­u­fac­tur­er Nat­co Phar­ma was hit with a warn­ing let­ter ear­li­er this month over vi­o­la­tions at its fa­cil­i­ty in the In­di­an state of Telan­gana, fol­low­ing an in­suf­fi­cient re­sponse to an FDA Form 483 last fall.

Un­til the drug­mak­er shows how it fixed the is­sues in the warn­ing let­ter, Nat­co has sus­pend­ed mak­ing prod­ucts at the fa­cil­i­ty for the US, the agency said.

Among the vi­o­la­tions that were laid out in the April 8 let­ter, the FDA said the fa­cil­i­ty failed to ad­e­quate­ly clean, san­i­tize or ster­il­ize equip­ment at the rate that would pre­vent con­t­a­m­i­na­tion or mal­func­tion. It al­so said Nat­co didn’t ad­e­quate­ly in­ves­ti­gate un­ex­plained dis­crep­an­cies in batch­es of prod­uct, in­clud­ing miss­ing records.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER